NCT06688422 Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
| NCT ID | NCT06688422 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cooper Health System |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-12-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of advanced non-small-cell lung cancer * Performance status (ECOG 0-1) * Eligible for concurrent chemotherapy and radiation * 18 years or older Exclusion Criteria: * Previous lung or thoracic surgery * Enrollment in another pulmonary intervention trial * Home oxygen usage prior to enrolment * Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging * Presence of active respiratory tract infection * Uncontrolled nausea and vomiting * Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy * Inability or unwillingness of individual to give written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06688422 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06688422 currently recruiting?
Yes, NCT06688422 is actively recruiting participants. Contact the research team at bakalov-veli@cooperhealth.edu for enrollment information.
Where is the NCT06688422 trial being conducted?
This trial is being conducted at Camden, United States.
Who is sponsoring the NCT06688422 clinical trial?
NCT06688422 is sponsored by The Cooper Health System. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.